A brace of popular science articles on aging research were recently published at the Economist. Like many of these views from a distance written by journalists on the outside, peering into the field, one must assume that its existence is largely the result of the sizable investments made over the last two years into the development of therapies based on partial reprogramming. The Altos Labs funding in particular represented a meaningful fraction of all investment into biotech made that year. That tends to attract attention. From there, an investigator would notice an additional broad focus on cellular senescence, many companies and research groups working towards the development of <a href="https://www.fightaging.org/archives/2017/09/senolytic-therapies-to-clear-senescent-cells-will-transform-the-field-of-medic…
A Outsider's Popular Science View of the Longevity Industry and Academia
A brace of popular science articles on aging research were recently published at the Economist. Like many of these views from a distance written by journalists on the outside, peering into the field, one must assume that its existence is largely the result of the sizable investments made over the last two years into the development of therapies based on partial reprogramming. The Altos Labs funding in particular represented a meaningful fraction of all investment into biotech made that year. That tends to attract attention. From there, an investigator would notice an additional broad focus on cellular senescence, many companies and research groups working towards the development of <a href="https://www.fightaging.org/archives/2017/09/senolytic-therapies-to-clear-senescent-cells-will-transform-the-field-of-medic…